Jean Luc Meynard

Summary

Country: France

Publications

  1. doi request reprint Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial
    Jean Luc Meynard
    Hopital Saint Antoine, AP HP, Paris, France
    J Antimicrob Chemother 65:125-8. 2010
  2. doi request reprint Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    J Antimicrob Chemother 63:579-84. 2009
  3. ncbi request reprint Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics
    J L Meynard
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, INSERM U 444, Faculte de Medecine Saint Antoine, and Laboratoire de Bacteriologie, Hopital Saint Antoine, Paris, France
    HIV Med 4:127-32. 2003
  4. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
  5. ncbi request reprint Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
  6. ncbi request reprint Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen
    Karine Lacombe
    Assistance Publique, Hopitaux de Paris, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris F 75012, France
    AIDS 19:1107-8. 2005
  7. ncbi request reprint Clinically relevant interpretation of genotype for resistance to abacavir
    Francoise Brun-Vezinet
    Department of Virology, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1795-802. 2003
  8. doi request reprint Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use
    Anders Boyd
    INSERM UMR S707, Paris, France
    Antivir Ther 15:963-74. 2010
  9. doi request reprint Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients
    Jerome Pacanowski
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, AP HP, Paris, France
    J Acquir Immune Defic Syndr 59:360-7. 2012
  10. pmc Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010

Detail Information

Publications27

  1. doi request reprint Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial
    Jean Luc Meynard
    Hopital Saint Antoine, AP HP, Paris, France
    J Antimicrob Chemother 65:125-8. 2010
    ..It is debated whether a risk of protease inhibitor mutation selection in proviral DNA exists during intermittent HIV-1 viraemia thereby impacting long-term virological control...
  2. doi request reprint Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    J Antimicrob Chemother 63:579-84. 2009
    ..However, data evaluating the impact of liver fibrosis stages on the plasma efavirenz level are lacking...
  3. ncbi request reprint Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics
    J L Meynard
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, INSERM U 444, Faculte de Medecine Saint Antoine, and Laboratoire de Bacteriologie, Hopital Saint Antoine, Paris, France
    HIV Med 4:127-32. 2003
    ..2. to identify risk factors for bacteraemia in this setting...
  4. ncbi request reprint Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
    Jean Luc Meynard
    INSERM SC4, Hopital Saint Antoine, Paris, France
    AIDS 16:727-36. 2002
    ..To assess the respective value of phenotype versus genotype versus standard of care for choosing antiretroviral therapy in patients failing protease inhibitor-containing regimens...
  5. ncbi request reprint Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
    ..To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed...
  6. ncbi request reprint Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen
    Karine Lacombe
    Assistance Publique, Hopitaux de Paris, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris F 75012, France
    AIDS 19:1107-8. 2005
    ..Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg...
  7. ncbi request reprint Clinically relevant interpretation of genotype for resistance to abacavir
    Francoise Brun-Vezinet
    Department of Virology, Bichat Claude Bernard Hospital, Paris, France
    AIDS 17:1795-802. 2003
    ..To develop a stepwise methodology for the development and validation of clinically relevant genotypic score for resistance to antiretroviral drugs and to apply this approach to the genotypic resistance to abacavir...
  8. doi request reprint Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use
    Anders Boyd
    INSERM UMR S707, Paris, France
    Antivir Ther 15:963-74. 2010
    ..The effect of TDF on liver fibrosis in 148 HIV-HBV-coinfected patients was prospectively evaluated using Fibrometer∆ scores and liver biopsies in a subset of patients...
  9. doi request reprint Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients
    Jerome Pacanowski
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, AP HP, Paris, France
    J Acquir Immune Defic Syndr 59:360-7. 2012
    ..In HIV-infected patients, data on immunogenicity of Yellow fever immunization are scarce, and there is conflicting evidence of the influence of CD4 T-cell count and plasma HIV RNA on neutralizing antibody titer (NT) after vaccine injection...
  10. pmc Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010
    ..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
  11. doi request reprint Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study
    Marguerite Guiguet
    INSERM, U, Paris, France
    AIDS 26:2345-50. 2012
    ..We aimed to determine the effectiveness of boosted protease inhibitor monotherapy (BPIMT) initiated as a maintenance strategy in routine care and identify predictive factors of failure...
  12. pmc High variability of plasma drug concentrations in dual protease inhibitor regimens
    Jean Baptiste Guiard-Schmid
    Department of Clinical Infectious and Tropical Diseases, Tenon Hospital, Paris, France
    Antimicrob Agents Chemother 47:986-90. 2003
    ....
  13. doi request reprint Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir
    Jean Luc Meynard
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 7:311-6. 2008
    ..This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks...
  14. pmc Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
    Beatrice Labrosse
    INSERM U552, Unité de Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 80:8807-19. 2006
    ..Thus, the envelope genetic context appears to play a critical role in the selection of HR1 mutations and the expression of ENF resistance, thereby conditioning the evolution of HIV-1 under fusion inhibitor selective pressure...
  15. ncbi request reprint Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients
    Nadia Valin
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    AIDS 24:1519-25. 2010
    ....
  16. doi request reprint Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial
    Jean Luc Meynard
    Service des Maladies Infectieuses, Hopital Saint Antoine, Faculte de Medecine Pierre et Marie Curie, Paris, France
    J Antimicrob Chemother 65:2436-44. 2010
    ..We evaluated a monotherapy maintenance regimen with lopinavir/ritonavir versus continuing current combined antiretroviral treatment (cART) in HIV patients with suppressed plasma HIV-1 RNA...
  17. ncbi request reprint Non-O:1 and non-O:139 Vibrio cholerae septicemia and pyomyositis in an immunodeficient traveler returning from Tunisia
    Carine Couzigou
    Unit of Infectious Diseases and Tropical Medicine, Faculte de Medecine Paris XII, Assistance Publique Hopitaux de Paris, Hopital Paul Brousse, 12 avenue PV Couturier, 94804 Villejuif, France
    Travel Med Infect Dis 5:44-6. 2007
  18. doi request reprint Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  19. ncbi request reprint Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis
    Laurence Fardet
    Hopital Saint Antoine, France
    AIDS 24:1299-306. 2010
    ..To describe features of reactive haemophagocytic syndrome (RHS) in HIV-1-infected adult patients. To compare characteristics of patients with malignancy-associated RHS and infection-associated RHS...
  20. doi request reprint Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  21. ncbi request reprint Fanconi syndrome and renal failure induced by tenofovir: a first case report
    David Verhelst
    Department of Nephrology, Hopital Tenon AP HP, Paris, France
    Am J Kidney Dis 40:1331-3. 2002
    ....
  22. doi request reprint Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy
    Moise Desvarieux
    aDepartment of Epidemiology, Columbia University, Mailman School of Public Health, New York, USA bInserm U 738 and École des Hautes Études en Santé Publique cAP HP Department of Cardiology, Hopital Saint Antoine, F 75012, Paris, France dUPMC Univ Paris 06, Paris F75012 eAPHP Department of Infectious and Tropical Diseases, Hôpital Saint Antoine fAPHP Hôpital Tenon, Service de Biochimie et Hormonologie, Paris F75020 gInserm UMR_S938, Paris F 75012 hInserm U970, Paris Cardiovascular Research Center, and Paris Descartes University iAP HP Centre d Investigation Clinique Paris EST 9304, Hopital Pitie Salpetriere, Paris, France jDepartment of Medicine, University of Cambridge, Cambridge, UK kInserm UMR S707, Paris, France
    AIDS 27:2603-14. 2013
    ....
  23. ncbi request reprint Campylobacter bacteremia: clinical features and factors associated with fatal outcome
    Jerome Pacanowski
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Paris, France
    Clin Infect Dis 47:790-6. 2008
    ..Campylobacter bacteremia is uncommon. The influence of underlying conditions and of the impact of antibiotics on infection outcome are not known...
  24. ncbi request reprint Urolithiasis in HIV-positive patients treated with atazanavir
    Carine Couzigou
    Service des Maladies Infectieuses et Tropicales, AP HP, Hopital Paul Brousse, Villejuif, France
    Clin Infect Dis 45:e105-8. 2007
    ..Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization...
  25. ncbi request reprint [Early diagnosis and prevention of comorbidities among HIV-infected patients: the Orchestra Saint-Antoine Program]
    L Fonquernie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Universite Pierre et Marie Curie Paris VI, APHP, 184, 75012 Paris, France
    Med Mal Infect 37:S229-36. 2007
    ..The Saint-Antoine Orchestra Program aims at improving the clinical management of HIV-infected patients through access to care, prevention and early diagnosis of comorbidities...
  26. ncbi request reprint [The use of microbiological tools for the diagnosis of nosocomial pulmonary infections]
    C Deschamps
    Service des Maladies Infectieuses, Hopital Saint Antoine, Paris
    Presse Med 33:1505-10. 2004
    ..To assess the use of microbiological examinations, notably serology, in the etiological diagnosis of pulmonary diseases in a department of infectious diseases...
  27. doi request reprint Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity
    S Malak
    Service d Hématologie et de Thérapie Cellulaire, AP HP, Hôpital Saint Antoine and UPMC Université Paris 06, Paris, France
    Scand J Immunol 68:337-44. 2008
    ..04). In conclusion, HIV-associated TMA with severe ADAMTS13 deficiency have less AIDS-related complications and a higher CD4(+) T cell count. TMA prognosis is better and comparable to this of idiopathic forms...